Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.38 |
| ▸ | TMPRSS15 | P98073 | 3/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.35 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.35 |
| ▸ | GART | P22102 | 1/20 | 0.35 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.35 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38757 | 0.99 | ITGB3 (0.39) | CA2CA1ITGB3ITGA2BTMPRSS15 | |
| SCHEMBL43738 | 0.98 | ITGB3 (0.38) | CA2CA1ITGB3ITGA2BTMPRSS15 | |
| SCHEMBL43739 | 0.90 | MAPT (0.36) | CA2CA1ITGB3ITGA2BTMPRSS15 | |
| SCHEMBL47172 | 0.83 | SMN1; SMN2 (0.42) | TMPRSS15FOLH1NPC1MAPTRAB9A | |
| SCHEMBL14821754 | 0.83 | CA2 (0.40) | CA2CA1ITGB3ITGA2BTMPRSS15 | |
| SCHEMBL14821760 | 0.83 | CA2 (0.40) | CA2CA1ITGB3ITGA2BTMPRSS15 | |
| SCHEMBL12202642 | 0.81 | MAPT (0.38) | NPC1MAPTRAB9APPARGLTA4H | |
| SCHEMBL38682 | 0.80 | MAPT (0.43) | NPC1MAPTRAB9ALTA4HPRSS1 | |
| SCHEMBL14821755 | 0.78 | ITGB3 (0.41) | CA2CA1ITGB3ITGA2BTMPRSS15 | |
| SCHEMBL14821757 | 0.78 | ITGB3 (0.41) | CA2CA1ITGB3ITGA2BTMPRSS15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426390-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN THERAPEUTICS GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-8034797-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN PHARMA GMBH (CH) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | CA2 3331/4885CA1 3913/4885ITGB3 4523/4885 |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | CA2 3331/4885CA1 3913/4885ITGB3 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.